Corline Biomedical AB

Stockholm Stock Exchange CLBIO.ST

Corline Biomedical AB Total Non-Current Liabilities for the year ending December 31, 2023

Corline Biomedical AB Total Non-Current Liabilities is NA for the year ending December 31, 2023. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Corline Biomedical AB Total Non-Current Liabilities for the year ending December 31, 2022 was USD 414.57 K.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

Stockholm Stock Exchange: CLBIO.ST

Corline Biomedical AB

CEO	Dr. Henrik Nittmar Ph.D.
IPO Date	June 3, 2015
Location	Sweden
Headquarters	Lefflersgatan 5
Employees	13
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Composite Materials Medical Instruments Pharmaceuticals Plastics

Description

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; CHC, which is used for the treatment of soft tissue injuries; medical devices; and CHS, a coronary stent. The company was founded in 1991 and is based in Uppsala, Sweden.

Key trends

Past 5 years